Utilising Network Pharmacology to Explore Underlying Mechanism of Astragalus membranaceus in Improving Sepsis-Induced Inflammatory Response by Regulating the Balance of IκBα and NF-κB in Rats

Haiyang Yu 1, Qihua Ling 2, Jingwen Cai 2, Mengzhi Zhang 3, Huaiquan Liu 1, and Yunzhi Chen 1

1. Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550025, China
2. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3. The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

Correspondence should be addressed to Yunzhi Chen; chenyunzhi270@gzy.edu.cn

Received 2 May 2021; Revised 4 November 2021; Accepted 30 November 2021; Published 31 March 2022

Objective. The purpose of the present study was to explore the mechanism of Astragalus membranaceus in the treatment of sepsis. Methods. We searched the active components and targets of Astragalus membranaceus using the TCMSP and BATMAN databases. Then, the GeneCards, MalaCards, and OMIM databases were used to screen out relevant targets of sepsis. The common targets of the former two gene sets were uploaded to the STRING database to create an interaction network. DAVID was used to perform KEGG enrichment analysis of the core targets. Based on the results of KEGG and previous studies, key pathways for the development of sepsis were identified and experimentally validated. Result. We obtained 3,370 sepsis-related targets in databases and 59 active components in Astragalus membranaceus through data mining, corresponding to 1,130 targets. The intersection of the two types of targets led to a total of 318 common targets and 84 core targets were obtained after screening again. The KEGG and previous studies showed that these 84 core targets were involved in sepsis by regulating TNF, MAPK, and PI3K pathways. TNF, MAPK8, NF-κB, and IκBa are crucial in sepsis. Experimental validation demonstrated that some markers in sepsis model rats were improved after the intervention with Astragalus granules and their chemical components. Among them, IL-1β, IL-6, and TNF-α in rat serum were reduced. The mRNA and protein expression of TNF-α, IL-6, MMP9, MAPK8, and NF-κB were reduced in rat blood. However, the mRNA and protein expression of IκBa and PI3K were increased in rat blood. Conclusion. The AST could affect the TNF, PI3K, and MAPK pathway cascade responses centred on IκBa and NF-κB, attenuate the expression of IL-6 and MMP9, and interfere with the inflammatory response during sepsis.

1. Introduction

Sepsis is a systemic inflammatory disease caused by the overactivation of the immune system and a cascade of inflammatory molecules released in the body under stress conditions, such as infection by pathogenic microorganisms, trauma, or shock. Without timely and effective treatment, sepsis can develop into severe sepsis and threaten the patient’s life [1, 2]. Epidemiology has shown that there are more than 30 million patients with sepsis worldwide [3]. Currently, the academic community suggests that excessive activation of the inflammatory response [4], immune dysfunction [5], and coagulation dysfunction [6] affect the prognosis of patients with sepsis. Clinically, the main treatment for sepsis is allopathic based on antibiotics. However, with the increasing number of drug-resistant strains, the abuse of antibacterial drugs, the development of new antibacterial drugs, and the relative lag in clinical application, the prognosis of patients with sepsis is still unsatisfactory [7].
*Astragalus membranaceus* (AST) is a Chinese herb that is effective in treating sepsis. AST is the dry root of *Astragalus membranaceus* (Fisch.) Bge. var. mongholicus (Bge.) Hsiao. Modern pharmacological studies have shown that AST and its constituents have good pharmacological effects on organ damage caused by sepsis. Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction by inhibiting RhoA/NLRP3 inflammasome signal transduction [8]. *Astragalus* polysaccharides have a protective effect on septic heart dysfunction by inhibiting the TLR4/NF-κB binding inducible nitric oxide synthase and interleukin-1. Liver, alleviating sepsis caused by cecal ligation and puncture [10].

Network pharmacology is a discipline that uses network visualisation and other technologies to reveal the complex biological network relationship among drugs, genes, diseases, and targets [11]. Network pharmacology can analyse drugs acting on different targets, cells, and organs at the molecular and genetic levels as well as predict and reveal the action and mechanisms of drugs. Network pharmacology can be used to construct a drug-target network based on the structure and efficacy of drugs and effectively predict the medicinal components and mechanism of action of traditional Chinese medicines and their compound preparations [12]. Therefore, we explored the protective effect of AST on the body. This study used network pharmacology methods to predict the targets and pathways of multiple compounds in AST. By constructing a "compound-target-disease" network, we were able to further clarify the improvement mechanism of AST in the process of sepsis. At the same time, we intragastrically administered AST granules to SD rats for one week and then constructed a sepsis model by tail vein injection of LPS. Finally, crucial gene changes were detected to explore the protective effect of AST on sepsis.

### 2. Materials and Methods

#### 2.1. The Chemical Composition of AST and Its Targets.

The main chemical components of AST were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (http://lsp.nwu.edu.cn/tcmsp.php) [13] and Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN) [14] (http://bionet.ncl.ac.uk/batman-tcm/). Based on the pharmacokinetic parameters of drug absorption, distribution, metabolism, and toxicity in the human body [15], oral bioavailability (OB) ≥ 30% and druglikeness (DL) ≥ 0.18 were used as the screening conditions for chemical components in TCMSP database. Adjusted \( P < 0.05 \) was used as the screening condition for chemical components in BATMAN database [18]. According to the screening conditions, the effective active components of AST were initially screened. If the screened composition has no target, then we delete it.

#### 2.2. Search for Sepsis-Related Targets. The Online Mendelian Inheritance in Man (OMIM, https://www.omim.org/) and the Human Disease Database (MalaCards, https://www.malaCards.org/), and the Human Gene Database (GeneCards, https://www.genecards.org/) were the searched target genes using “sepsis” as a keyword. After taking intersections of sepsis-related targets with AST targets, we obtained potential genes for AST in the treatment of sepsis.

#### 2.3. Protein-Protein Interaction (PPI) Construction and Screening. The intersecting genes were imported into the STRING database 11.5 (http://string.embl.de/). Species was set as human; the minimum interaction threshold was set to “highest confidence” (>0.9) [19]; and the disconnected nodes in the network were hidden. In addition, a secondary screen was performed to obtain more accurate targets. The screening criteria were as follows: targets with a degree, betweenness, and closeness greater than the median value of all the nodes in the intersection network were selected as core targets to build the protein-protein interaction (PPI) network [20].

#### 2.4. Construction of the Drug-Target-Disease Network Graph.

We imported the core genes and their corresponding components into Cytoscape 3.6.1 in order to construct the Drug-Target-Disease Network graph.

#### 2.5. Kyoto Encyclopedia of Genes and Genomes (KEGG) Enrichment Analysis. To further understand the specific roles of the screened intersection networks in terms of gene function and related signaling pathways, KEGG pathway enrichment analysis was performed on the genes associated with the core targets using DAVID. A threshold of \( P < 0.05 \) was set as statistically significant. Potential connections between pathways were also found by searching previous literature in PubMed, and the essential targets of the significant pathways were visualised using Cytoscape 3.6.1.

#### 2.6. Molecular Docking. Molecular docking was performed to validate the important targets screened by KEGG analysis as well as their more closely related chemically synthesised components. Protein targets were obtained from the RCSB PDB (https://www.rcsb.org/) database, and compounds were obtained from the TCMS database. The proteins and small molecules were optimised using SYBYL-X.2.0 software, and molecular docking was performed using the SurflexDock module. The interaction of the active ingredients with the target proteins was scored according to the total score scoring function, with larger total score values indicating better matching of the small molecule compounds to the more significant protein. Generally, a score above 4.0 is considered to indicate some binding activity, and a value greater than 5.0 indicates that the molecule has strong binding to the target [21, 22].
2.7. Experimental Validation

2.7.1. Main Reagents and Instruments. We used the following drugs and reagents: cycloeucalenol, encecalin, kaempferol (Chengdu Push Biotechnology Co., Ltd, PS210726-09, PS210726-08, and PS0111676), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor (TNF-α) enzyme-linked immunoassay (ELISA) kits (Wuhan Genome Biotechnology Co., Ltd., JYM0419Ra, JYM0646Ra, and JYM0635Ra), LPS (Solarbio, L8880), rabbit polyclonal antibodies TNF-α, MAPK8, P3K, IL-6 (Affinity, No. AF7014, AF6089, AF6241, and DF6087), GAPDH (Hangzhou Xianzhi Biological Co., Ltd., No. AB-P-R 001), rabbit monoclonal antibody 1xBa, MMP9, NF-κB, and β Actin (abcam No. Ab32518, Ab76003, Ab32360 and Ab6276), Methanol (Merck, Germany), kaempferol (Chengdu Push Bio-Technology Co., Ltd, No.AB-P-R001), rabbit AF7014, DF6089, AF6241, and DF6087), GAPDH (Hangzhou Xianzhi Biological Co., Ltd., No. AB-P-R 001), rabbit monoclonal antibody 1xBa, MMP9, NF-κB, and β Actin (abcam No. Ab32518, Ab76003, Ab32360 and Ab6276), Methanol (Merck, Germany), Astragalus granules were purchased from Baili Pharmaceutical Group in China (authorised document number: country medicine accurate character Z20003380), excipient (Referring to Liang Jun’s production process [23], the auxiliaries were made in Guizhou University of Traditional Chinese Medicine), T’Rlizol (Ambion, 15596-026), HiScript Reverse Transcriptase (VAZYM, R101-01/02), 5X HiScript Buffer (VAZYM, R101-01/02), ddH2O (geneopoeia, C1D230A), Ribonuclease Inhibitor (TransGen, A1101), dNTPs (TIANGEN, CD117), SYBR Green Master Mix (VAZYM, Q111-02), Taq Plus DNA Polymerase (TIANGEN, ET105-01), DL2000 DNA Marker (TIANGEN, MD114-02), and Random Primer (TAKARA, 3801); Primers (Wuhan Tsingke Biological Company, China).

We used the following instruments: HBS-1096A ELISA Analytical Instrument (Thermo Electron Corporation, America), adjustable micropipette (Glison, France), high-speed and low-temperature centrifuge (Eppendorf, Germany), low-speed centrifuge (Shanghai Anting Technology Instrument Factory, China), thermostat (Beijing Liuyi Company, China), 4°C refrigerators (Zhongke Meiling, China), 37°C incubation box (Henan Jinbo, China), and QuantStudio 6 real-time quantitative PCR instrument (ABI, America); High-Performance Liquid Chromatography (waters, America) and PCR instrument (Dongsheng Innovative Biotechnology Co., Ltd., China).

2.7.2. Determining Chemical Compounds and LD50 Prediction Based on HPLC and Discovery Studio. Dissolve 4 g of Astragalus granules in 10 mL of ultrapure water, add methanol to fix the volume to 50 mL, extract with ultrasound for 2 hours, and then place in a centrifuge at 4°C and centrifuge at 12000 rpm for 10 min. 1 mg standard product of cycloeucalenol is dissolved in 1 mL methanol. 1 mg standard product of encecalin is dissolved in 1 mL methanol. 1 mg standard product of kaempferol is dissolved in 1 mL methanol.

For the detection of cycloeucalenol, a Waters model 2695 HPLC with a Waters 2424 evaporative light detector was used. The chromatographic column is Diamonsil C18 (2) (250 * 4.6 mm, 5 μm), the mobile phase is methanol, column temperature is 60°C, the flow rate is 1 mL/min, the drift tube temperature is 80°C, nebuliser temperature is 30°C, the nitrogen flow rate and gain is set to 25 psi and 100, respectively, and the injection volume is 10 μL.

Encecalin was detected using a Waters model 2695 HPLC with a DAD detector. The chromatographic column is Diamonsil C18 (2) (250 * 4.6 mm, 5 μm), the flow rate is 1 mL/min, the column temperature is 35°C, the detection wavelength is 254 nm, and the injection volume is 10 μL. The gradient elution process is shown in Table 1.

The instrument used for the determination of kaempferol was a Waters model 2695 HPLC with DAD detector. The chromatographic column was a Diamonsil C18 (2) (250 * 4.6 mm, 5 μm) with a flow rate of 1 mL/min, a column temperature of 35°C, and a detection wavelength of 360 nm. The mobile phase was methanol:0.1% phosphoric acid in water:50:50, and the injection volume was 10 μL. Oral LD50 predictions for cycloeucalenol, encecalin, and kaempferol were performed in rats using Discovery Studio software to determine the subsequent dose to be administered [24], with 1/20th of the respective LD50 resultant dose being used as the final dose for subsequent pharmacological experiments [25].

2.7.3. Experimental Animals. Seventy SD male rats aged 8–9 weeks with bodyweight of (200 ± 30) g were used in this laboratory, all of which were provided by Changsha Tianqin Biotechnology Co. LTD. (animal production licence number: SCXK (Xiang) 2019-0014). According to the random number table method, they were randomly divided into 7 groups with 10 rats in each group, namely: control group, LPS group, LPS + Astragalus granules group, LPS + excipient group, LPS + cycloeucalenol group, LPS + encecalin group, and LPS + kaempferol group. The normal adult dosage of Astragalus granule is 8g per day. Based on the human-rat body surface area conversion, the daily dose for rats is 0.8 g/kg. Dissolve 8 g of Astragalus granules in 100 mL of water to prepare an aqueous solution of Astragalus granules at 80 mg/ml. This study was approved by the Medical Research Ethics Committee of the Second Affiliated Hospital of Nanchang University and the examination and approval no. review [2021], no. (A801).

2.7.4. Sepsis Model Preparation and Sampling. After a week of adaptive feeding, each group of rats was given the appropriate intervention. Astragalus granule (0.8 g/kg), excipient (0.8 g/kg), cycloeucalenol (350 mg/kg), encecalin (14.1 mg/kg), and kaempferol (6.9 mg/kg), respectively, were administered by gavage for one week. LPS modelling was performed on all rats except control group 24 h after the last administration. In the control group, only normal saline was injected into the tail vein. Rats in other groups were injected with 10 mg/kg of LPS through tail vein according to body weight [26]. Twenty-four hours after model establishment, all surviving rats in each group were anaesthetised for blood sampling.

2.7.5. Observing the General Situation and Survival Rate of Rats. Behavior change, fur color, and mental state before and after modelling were observed. Death after modelling was recorded, and survival curves of rats in each group were drawn.
Table 1: Elution gradient.

| Time (min) | %A (water) | %B (methanol) |
|------------|------------|---------------|
| 0          | 80         | 20            |
| 8          | 0          | 100           |
| 13         | 0          | 100           |
| 15         | 80         | 20            |

2.7.6. Detection of Serum IL1β, IL-6, and TNF-α Levels in Rats by ELISA. After anaesthesia, abdominal aorta blood was taken and centrifuged. The supernatant was taken, and the contents of IL1β, IL-6, and TNF-α in serum were detected by ELISA kit. The operation was carried out in strict accordance with the instructions.

2.7.7. Real-Time Quantitative PCR Analysis. Total RNA was extracted from rat blood using a TRIzol kit (Takara) according to the manufacturer's instructions, reverse transcribed into cDNA using the PrimeScript RT kit with genomic decontamination, and then amplified by PCR. GAPDH was used as an internal reference gene to calculate the 2^(-ΔΔCt) value for IL-6, MAPK8, TNF-α, MMP9, PI3K, and NF-κB genes. β-actin was used as an internal reference gene to calculate the 2^(-ΔΔCt) value for 18S gene. The specific primers were as follows (as shown in Table 2).

2.7.8. Western Blot. Use RIPA lystate to lyse the cells in the blood, use the BCA kit to determine the protein concentration, add the prepared protein sample to a 10% gel for electrophoresis, transfer the membrane, and then block in 5% skim milk for 2 hours. PVDF membranes of 0.45 μm size were immersed in primary antibody incubation solution and incubated overnight at 4°C. Antibody dilutions were as follows: GAPDH (1:1000), TNF (1:500), β-actin (1:200), MAPK8 (1:1000), PI3K (1:2000), NF-κB (1:1000), IL-6 (1:1000), 18S (1:5000), and MMP9 (1:5000). Add the corresponding secondary antibody, soak the PVDF membrane in the secondary antibody incubation solution, and incubate for 2 h at 37°C in a shaker. Finally, the film was washed with TBST and developed with ECL luminescence. The films were scanned, and the results were analysed by ImageJ software for gel imaging systems.

2.7.9. Statistical Methods. All data were processed by SPSS 22.0 statistical software. The measured data are expressed as the mean ± standard deviation (mean ± SD). One-way ANOVA was used to compare multiple groups when the data were normally distributed and homogeneity of variance. Survival analysis was performed using the log-rank (Mantel–Cox) test function. Differences were indicated as statistically significant at P < 0.05.

3. Results and Discussion

3.1. Results

3.1.1. AST Chemical Composition and Its Targets. After screening, the TCMSP database contains 8 compounds and 111 targets, and the BATMAN database contains 51 compounds and 1081 targets. After removing the blank and duplicate targets, a total of 59 chemical components and 1130 drug targets were obtained (as shown in Table 3).

3.1.2. Potential Targets of AST for Sepsis. 2498, 771, and 183 targets associated with sepsis were obtained from GeneCards, MalaCards, and OMIM, respectively. A total of 3370 pathogenic genes were obtained after the removal of duplicates for these targets. A total of 318 intersecting genes were obtained after intersecting these pathogenic genes with the 1130 targets of AST. These are potential targets that can be used in the treatment of sepsis (as shown in Figure 1).

3.1.3. Protein-Protein Interaction (PPI) Network Construction and Screening. To further clarify the extent of the role of intersecting genes in the development of sepsis, we screened 318 intersection-based genes by the STRING database. Based on the magnitude of the median degree, betweenness, and closeness of individual genes in the entire network, we identified 84 core targets (as shown in Figure 2).

3.1.4. AST Active Ingredient Target-of-Action Disease Network Diagram. The 84 core targets and their corresponding 44 chemo-components were visualised using Cytoscape 3.6.1 software (as shown in Figure 3).

3.1.5. KEGG Result Presentation. KEGG analysis of the targets related to the treatment of sepsis by AST was performed using DAVID. Eighty-four markers were found to be involved in 104 signalling pathways (P < 0.05), mainly including cancer, the TNF signaling pathway, Chagas disease, influenza A, hepatitis B, leishmaniasis, the MAPK signaling pathway, proteoglycans in cancer, osteoclast differentiation, Tollas disease, osteoclast differentiation, influenza A, hepatitis B, leishmaniasis, the MAPK signaling pathway, proteoglycans in cancer, osteoclast differentiation, the Toll-like receptor signaling pathway, toxoplasmosis, Salmonella infection, nonalcoholic fatty liver disease (NAFLD), the prolactin signaling pathway, measles, the chemokine signaling pathway, pertussis, the HIF-1 signaling pathway, neurotrophin signaling pathway, the PI3K-Akt signaling pathway, etc. In this study, the top 20 KEGG signaling pathways were screened according to the count value to generate a map (as shown in Figure 4). Based on the KEGG results and summary of previous studies, we found the TNF, MAPK, and PI3K pathways in the pathogenesis of sepsis [27]. We finally identified 18S, MAPK8, NF-κB1, and TNF as possible indicators of sepsis development based on the frequency of 84 core targets in the TNF, MAPK, and PI3K pathways and relevant references [28–30]. In Figure 3, the compounds corresponding to these targets, include kaempferol, cycloexucaenol, cyperol, encecalin, gamma-sistosterol, and encecalin, may play an important therapeutic role. We identified the active components in the AST based on the core targets and mapped the network diagram of core targets, pathways, and components in conjunction with the KEGG results (as shown in Figure 5).
Table 2: Specific primer sequences for GAPDH, β-actin, MAPK8, NF-κB, IκBα, PI3K, TNF-α, IL-6, and MMP9.

| Gene     | Primer | Sequence (5′-3′)                          | PCR products (bp) |
|----------|--------|-------------------------------------------|-------------------|
| Rat GAPDH | Forward | ACAGCAACAGGGTGTTGGGAGC                     | 253               |
|          | Reverse | TTTGAGGGTGAGCGGAACTT                      |                   |
| Rat MAPK8 | Forward | ATTTGGAGGAGCGAATCAAG                      | 160               |
|          | Reverse | CTGCTGCTGCTATCCGAGGCC                    |                   |
| Rat NF-κB | Forward | TGACGGGAAGGGAAGAAATC                      | 211               |
|          | Reverse | TGAACAAACACGGAACGCTG                     |                   |
| Rat IκBα  | Forward | ATGCTACTGCTGGCACTG                        | 136               |
|          | Reverse | TTCAACAGGAGCGAGACG                       |                   |
| Rat PI3K  | Forward | GTGGTAGATGGCGAGGATCA                      | 126               |
|          | Reverse | CAGGGAGGTGTGGTGTGAA                      |                   |
| Rat TNF-α | Forward | CCGATTGGCCATTTCATACCA                     | 232               |
|          | Reverse | TCACAGAGCAATGCCACTCCAA                     |                   |
| Rat IL-6  | Forward | GTTGCTTCTGGAGGTACG                       | 102               |
|          | Reverse | TACTGCTGCTGCTGGGTGT                      |                   |
| Rat MMP9  | Forward | GCTGGGCTTAGATCATTCTTCAGT                  | 109               |
|          | Reverse | CAGATGCCTGGATCGCCCTTTGTATGCG              |                   |
| Rat β-actin| Forward | CACGATGGAGGGCGGGACTCATC                  | 240               |
|          | Reverse | TAAAGACCTCTATGCAAACACAGT                  |                   |

Table 3: The chemical composition of AST and its targets.

| Components | The number of target | Structural formula | Database |
|------------|----------------------|--------------------|----------|
| Mairin     | 1                    | ![Mairin](image)   | TCMSP    |
| Jaranol    | 9                    | ![Jaranol](image) | TCMSP    |
| Kaempferol | 51                   | ![Kaempferol](image) | TCMSP    |
| Isorhamnetin | 24               | ![Isorhamnetin](image) | TCMSP    |
| Bifendate  | 4                    | ![Bifendate](image) | TCMSP    |
Table 3: Continued.

| Components                                                                 | The number of target | Structural formula | Database |
|---------------------------------------------------------------------------|----------------------|--------------------|----------|
| 1,7-Dihydroxy-3,9-dimethoxy pterocarpene                                  | 3                    | ![Structural formula](image) | TCMSP    |
| (6aR,11aR)-9,10-Dimethoxy-6a,11a-dihydro-6H-benzofurano[3,2-c]chromen-3-ol | 18                   | ![Structural formula](image) | TCMSP    |
| (3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | 1                    | ![Structural formula](image) | TCMSP    |
| Tetradecane                                                               | 98                   | ![Structural formula](image) | BATMAN   |
| Tridecane                                                                | 98                   | ![Structural formula](image) | BATMAN   |
| 1,22-Docosanediol                                                         | 159                  | ![Structural formula](image) | BATMAN   |
| Ginsenoside                                                               | 19                   | ![Structural formula](image) | BATMAN   |
| (-)-Dicentrine                                                            | 47                   | ![Structural formula](image) | BATMAN   |
| Notoginsenoside                                                           | 1                    | ![Structural formula](image) | BATMAN   |
| (-)2d,4d,6d,8d-Tetramethyl undecanoic acid                                | 226                  | ![Structural formula](image) | BATMAN   |
| Sandaracopimarinol                                                        | 51                   | ![Structural formula](image) | BATMAN   |
| Ginsenoside Rb1                                                           | 1                    | ![Structural formula](image) | BATMAN   |
| Components                                | The number of target | Structural formula | Database |
|-------------------------------------------|----------------------|--------------------|----------|
| Dicapryl phthalate                        | 13                   | ![Structural formula](image) | BATMAN   |
| Cyperene                                  | 98                   | ![Structural formula](image) | BATMAN   |
| (-)-Trifara-9,14-diene                    | 98                   | ![Structural formula](image) | BATMAN   |
| Cycloeucalenol                            | 32                   | ![Structural formula](image) | BATMAN   |
| 4,4′-Diketo-3-hydroxy-beta-carotene       | 43                   | ![Structural formula](image) | BATMAN   |
| Nonadecanoic acid                         | 22                   | ![Structural formula](image) | BATMAN   |
| Quercetin                                 | 15                   | ![Structural formula](image) | BATMAN   |
| Notoginsenoside R3                        | 1                    | ![Structural formula](image) | BATMAN   |
| Diterterbutyl phthalate                   | 27                   | ![Structural formula](image) | BATMAN   |
| Hexadecanoic acid                         | 226                  | ![Structural formula](image) | BATMAN   |
| Dauricine                                 | 22                   | ![Structural formula](image) | BATMAN   |
| Components            | The number of target | Structural formula | Database |
|-----------------------|----------------------|--------------------|----------|
| 3,4-Dimethylbenzoic acid | 131                  | [structure image]   | BATMAN   |
| Notoginsenoside R1    | 1                    | [structure image]   | BATMAN   |
| Notoginsenoside A     | 1                    | [structure image]   | BATMAN   |
| Gypenoside Xvii       | 1                    | [structure image]   | BATMAN   |
| Epsilon-cadinene      | 98                   | [structure image]   | BATMAN   |
| 1-Tetradecanol        | 193                  | [structure image]   | BATMAN   |
| 1-Heptadecanol        | 159                  | [structure image]   | BATMAN   |
| N-Nonanol             | 159                  | [structure image]   | BATMAN   |
| Acetophenone          | 40                   | [structure image]   | BATMAN   |
| Encecalin             | 60                   | [structure image]   | BATMAN   |
| 20-Hexadecanoylingenol| 10                   | [structure image]   | BATMAN   |
| Components              | The number of target | Structural formula | Database |
|-------------------------|----------------------|--------------------|----------|
| Notoginsenoside R2      | 1                    | ![Structural formula](image) | BATMAN   |
| Elemicin                | 61                   | ![Structural formula](image) | BATMAN   |
| Sanchinoside B1         | 2                    | ![Structural formula](image) | BATMAN   |
| Alpha-cuparenol         | 4                    | ![Structural formula](image) | BATMAN   |
| Cyclododecanone         | 23                   | ![Structural formula](image) | BATMAN   |
| Stigmasterol            | 119                  | ![Structural formula](image) | BATMAN   |
| Panaxatriol             | 2                    | ![Structural formula](image) | BATMAN   |
| Panaxadiol              | 2                    | ![Structural formula](image) | BATMAN   |
| Heneicosanic acid       | 226                  | ![Structural formula](image) | BATMAN   |
Table 3: Continued.

| Components                                                                 | The number of target | Structural formula | Database |
|---------------------------------------------------------------------------|----------------------|--------------------|----------|
| Coprine                                                                   | 386                  | ![Chemical Structure](image1.png) | BATMAN   |
| 1,1,5,5-Tetramethyl-4-methano-2,3,4,6,7,10-hexahydrodronaphthalene       | 100                  | ![Chemical Structure](image2.png) | BATMAN   |
| Delta-guaiene                                                             | 98                   | ![Chemical Structure](image3.png) | BATMAN   |
| 1-Methyl-4-allyl-cyclohexane                                             | 98                   | ![Chemical Structure](image4.png) | BATMAN   |
| Gamma-sitosterol                                                          | 35                   | ![Chemical Structure](image5.png) | BATMAN   |
| Pentadecanoic acid                                                        | 226                  | ![Chemical Structure](image6.png) | BATMAN   |
| Ginsenoside-Rb2                                                           | 1                    | ![Chemical Structure](image7.png) | BATMAN   |
| Cuparene                                                                  | 10                   | ![Chemical Structure](image8.png) | BATMAN   |
| Ginsenoside-Rd                                                            | 1                    | ![Chemical Structure](image9.png) | BATMAN   |
| Delta-elemene                                                             | 99                   | ![Chemical Structure](image10.png) | BATMAN   |
| Cyperol                                                                   | 33                   | ![Chemical Structure](image11.png) | BATMAN   |

The table lists the names of the chemical components within *Astragalus*, the number of corresponding targets, their structural formulas, and the databases from which they are sourced.
Figure 1: Intersecting genes of AST and sepsis. The blue circle on the left represents the target of AST. The yellow circles at the right represent sepsis targets. The intersection in the middle indicates the potential target of AST for the treatment of sepsis.

Figure 2: Protein-protein interaction of 318 genes is shown.
3.1.6. Molecular Docking. The main active components of AST obtained in Section 3.1.5 were γ-sitosterol, cycloeucalenol, kaempferol, encecalin, and cyperol. TNF, MAPK8 (JNK), NF-κB1, and IκBα were the critical genes identified in Section 3.1.5. The protein receptors and active compounds corresponding to IκBα (PID: 6Y1J), NF-κB (PID: 1NFK), TNF (PID: 1DU3), and MAPK8 (PID: 4G1W) were selected from the RSCB PDB database for molecular docking. The main active components in AST enter the active site during the docking process with the core targets, indicating that the main active components and the core targets demonstrate good binding, which verifies the reliability of the results of this study. The total score results are shown in Figure 6. Graph showing molecular docking results is given in Figure 7.

3.1.7. Experimental Validation

(1) Determination of Substances and Prediction of LD50 Based on HPLC and Discovery Studio for Chemistry Components. In chromatographic analysis, samples of Astragalus...
granules showed the same retention times as the standard products of cycloeucalenol, encecalin, and kaempferol (as shown in Figure 8).

According to the calculation by Discovery Studio, the oral LD50 of cycloeucalenol, encecalin, and kaempferol was 7 g/kg, 282.7 mg/kg, and 138.9 mg/kg, respectively.

(2) General Situation and Survival Analyses. Compared with the control group, rats in the LPS group, LPS + Astragalus granules group, LPS + excipient group, LPS + cycloeucalenol group, LPS + encecalin group, and LPS + kaempferol group have decreased diet and water consumption. LPS group and LPS + excipient group have the worst mental state and weakened activities, while LPS + Astragalus granules group and LPS + cycloeucalenol group situation was significantly improved. When the time to death of the rats within 24 hours was counted, a significant difference was found in the survival curve of LPS group compared to control group ($P < 0.01$). This demonstrated that LPS has a strong lethal effect. The survival rate was significantly improved with the

![KEGG bubble chart](image-url)
intervention of Astragalus granules and cycloeucalenol ($P < 0.05$) (as shown in Figure 9). This implied that Astragalus granules and cycloeucalenol could significantly reduce the toxicity of LPS in rats.

(3) Determination of the Serum IL-1β, IL-6, and TNF-α Levels in Rats by ELISA. IL-1β, IL-6, and TNF-α are critical inflammatory factors and biological markers of sepsis [31]. They can be used as a criterion for the success of the sepsis model. This study verified the expression of serum inflammatory factors in vivo in septicemic rats affected by sepsis. IL-1β, IL-6, and TNF-α of serum expression of biological markers were increased in the LPS group compared to that in the control group ($P < 0.01$). The levels of IL-1β, IL-6, and TNF-α were downregulated after Astragalus granules intervention ($P < 0.01$). Cycloeucalenol significantly inhibited IL-1β ($P < 0.01$) and also suppressed the elevation of IL-6 and TNF-α to some extent ($P < 0.05$). Encecalin significantly inhibited IL-1β ($P < 0.01$) and also suppressed the elevation of IL-6 to some extent ($P < 0.05$) (as shown in Figure 10).

(4) Detection of TNF-α, IL-6, MMP9, MAPK8, PI3K, NF-κB, and IκBa mRNA Expression in Rat Blood by Real-Time qPCR. The result showed that the targets of TNF-α, IL-6, MMP9, MAPK8 (JNK), and NF-κB in the blood of rats in the LPS group were significantly higher than those in the blood of rats in the control group ($P < 0.01$), and PI3K and IκBa were substantially lower than those in the blood of rats in the control group ($P < 0.01$). This trend was reversed after Astragalus granules intervention ($P < 0.01$). In addition, cycloeucalenol, encecalin, and kaempferol also regulate the expression of these genes in the blood of the sepsis model to varying degrees. Among them, cycloeucalenol significantly inhibited the mRNA expression of MMP9 ($P < 0.01$) and the mRNA expression of inhibited MAPK8, TNF-α, and IL-6 ($P < 0.05$). Cycloeucalenol significantly upregulated PI3K expression ($P < 0.01$) and IκBa ($P < 0.05$). Encecalin inhibited the upregulation of MMP9, NF-κB, and TNF-α ($P < 0.05$). Encecalin upregulated PI3K expression ($P < 0.05$). Kaempferol inhibited the elevation of NF-κB and IL-6 ($P < 0.05$). These manifestations illustrate that
Astragalus granules and their components can regulate the expression of these genes during transcription (as shown in Figure 11).

(5) The Protein Expression Levels of TNF-α, IL-6, MMP9, MAPK8, PI3K, NF-κB, and IκBα in Rat Blood. Our study revealed significant changes in blood protein expression of core targets such as TNF-α, IL-6, MMP9, MAPK8, PI3K, NF-κB, and IκBα in the LPS group after LPS intervention (P < 0.01). The protein expression of TNF-α, IL-6, MMP9, MAPK8, and NF-κB was significantly increased in the LPS group (P < 0.01), while the protein expression of PI3K and IκBα was significantly decreased (P < 0.01). These trends were significantly reversed in the LPS + Astragalus granules group after intervention with Astragalus granules (P < 0.01).

In addition, cycloeucalenol, encecalin, and kaempferol can also regulate the expression of related proteins in the blood of the sepsis model to varying degrees. Among them, cycloeucalenol significantly inhibited the expression of MMP9 (P < 0.01) and inhibited MAPK8, TNF-α, and IL-6 (P < 0.05). Cycloeucalenol significantly upregulated PI3K expression (P < 0.01) and IκBα (P < 0.05). Encecalin significantly inhibited the upregulation of MMP9 (P < 0.05), TNF-α, and NF-κB (P < 0.01). Encecalin significantly upregulated PI3K expression (P < 0.01). Kaempferol significantly inhibited NF-κB (P < 0.01) and IL-6 (P < 0.05) (as shown in Figure 12).

3.2 Discussion. As an inflammatory blood disease, the occurrence and development of sepsis is the result of multiple protein molecules and multiple signal pathways modulating on various cell biological behaviors. AST, a traditional Chinese medicine, has a significant effect on sepsis, and it can play a role in the treatment of sepsis in various ways. Recent studies have shown that there are many components in the AST that can slow the progression of sepsis. The literature has demonstrated that kaempferol, stigmasterol, (-)-dicentrine, 1-tetradecanol, cyperene, tetracane, elemicin, and other components can relieve the inflammatory response of the body. Stigmasterol can effectively inhibit the inflammatory response induced by LPS.
and has an excellent regulatory impact on the abnormal levels of serum liver enzyme markers, alanine aminotransferase, aspartate aminotransferase, ALT, and AST [32]. Kaempferol can be used to treat acute and chronic inflammatory damage to many organs, such as the colon, liver, and lung [33]. (-)-Dicentrine can inhibit the MAPK/Akt pathway activated by LPS to a certain extent and relieve the body’s inflammatory response [34]. The tetrade cane family can affect PPARγ signaling and weaken tissue damage in the intestine [35]. Cyperene has an excellent protective effect on LPS-induced inflammation and oxidative stress damage in astrocytes [36]. Elemicin and other components have significant effects on inhibiting pneumonia, reducing serum IFN-γ and IL-4 levels, and enhancing their antioxidant activity [37]. γ-sitosterol can inhibit the expression of NF-κB and the synthesis of TNF-α in macrophages [38]. AST can alleviate inflammatory damage in patients with sepsis by regulating the MAPK pathway, PPARγ signaling, IFN-γ, and IL-4.

After analysing the PPI network, it was found that TNF, MAPK14, AKT1, MAPK8 (JNK), and NF-κB1 were important in the progression of the disease. TNF is a bipolar molecule derived from macrophages and immune cells. When the body is activated during infection or tissue damage, it can transmit signals via ligands and receptors back to cells, causing subsequent inflammatory cascade reactions [39]. TNF-α can not only induce a massive release of a variety of inflammatory factors and stimulate the development of inflammation [40] but also directly consume the antioxidant substance glutathione in the body [41] and stimulate neutrophils and endothelial cells to release oxygen free radicals and other free radicals [42]. MAPK14 (p38) and MAPK8 (JNK) can receive and prolong the path and duration of TNF signal transduction and jointly affect the level of systemic

Figure 8: HPLC chromatogram. (a) Cycloeucalenol standard chromatogram. (b) Cycloeucalenol chromatogram in Astragalus granules. (c) Encecalin standard chromatogram. (d) Encecalin chromatogram in Astragalus granules. (e) Kaempferol standard chromatogram. (f) Kaempferol chromatogram in Astragalus granules.

Figure 9: Effect of Astragalus granules and its components on the survival rate of rats with sepsis (n = 10). a: Control group; b: LPS group; c: LPS + Astragalus granules group; d: LPS + excipient group; e: LPS + cycloeucalenol group; f: LPS + Encecalin group; g: LPS + Kaempferol group. *P < 0.05, compared with the LPS group. **P < 0.01, compared with LPS group. ##P < 0.01, compared with control group.
inflammation response, the area of tissue damage, and the degree of organ function impairment by activating NF-κB [43]. In this process, AKT1 (also called protein kinase B or PKB) activates IκBα under the action of PI3K. IκBα can pass through the 300 amino acid residue Rel homology region. The Rel homology domain (RHD) interacts with IκBα to prevent the NF-κB dimer from entering the nucleus to exert its negative feedback regulation on NF-κB [44, 45]. In summary, the above targets will eventually activate the PI3k, MAPK, TNF, and NF-κB pathways to aggravate the inflammatory response in the body.

According to the KEGG results and previous literature, we found that the PI3K signaling pathway, MAPK signaling pathway, and TNF signaling pathway played essential roles in the pathogenesis of sepsis. The PI3K (phosphatidylinositol-3-kinase) pathway is a crucial signaling pathway in the body, and it maintains tissue homeostasis by regulating protein phosphorylation, methylation, and ubiquitination [44]. In sepsis, activation of the PI3K pathway can reduce damage to the diaphragm [46], myocardium [47], lung [48], and other tissues and organs by inhibiting the degradation of IκBα. Mitogen-activated protein kinase (MAPK) is an essential member of the intracellular signaling protein network that mediates extracellular stimuli to intracellular responses. The activation of its subtype JNK is based on thermal-induced apoptosis of macrophages, and the release of IL-6, MMP9, TNF-α, and other inflammatory factors further aggravates organ damage in patients with sepsis [49]. These inflammatory mediators in blood circulation mediate the damage to host cells, tissues, and organs and act as triggers of subsequent cascade reactions [50]. IL-6 is an essential indicator for evaluating the degree of the inflammatory response [51], and it can interact with a variety of cytokines, initiate a series of signal transduction mechanisms, and form a complex network of cytokines, which can mediate endothelial cells and monocytes [52]. The production of chemotactic protein (MCP)-1 can also recruit peripheral blood mononuclear cells to accumulate at the site of inflammation, activate specific white blood cells, and initiate and maintain an inflammatory response [53]. TNF-α can effectively control the increase in MMP9 expression after initiation by MAPK8 [INK] [54], and the increase in MMP9 can promote a further inflammatory response and degrade extracellular matrix components [55]. In addition, TNF-α in combination with TNFR leads to the high expression of the transcription factor NF-κB and aggravates the inflammatory response throughout the body [56]. Under normal circumstances, the combination of the NF-κB dimer and IκBα in resting cells masks the nuclear localisation signal of NF-κB, but when stimulated, IκBα is degraded, so the NF-κB dimer is released into the nucleus and activates the transcription of target genes [57]. After NF-κB is released, it initiates MAPK8 (JNK) and aggravates the inflammatory response [58]. The PI3K pathway is critical for synthesising IκBα [59, 60]. Therefore, these three factors do not independently affect the physiological and pathological changes of the body. During the development of sepsis, these pathways are mostly interrelated and intertwined. The TNF signaling pathway is an essential condition for the early activation of the MAPK and PI3K signaling pathways, and it also establishes a connection between the PI3K and MAPK signaling pathways in the inflammatory response by regulating the hub of the NF-κB pathway. The TNF, MAPK, and PI3K signaling pathways are connected through IκBα and NF-κB. The interaction between these pathways in the pathogenesis of sepsis determines the degree of widespread inflammation throughout the body, and exchange among these three pathways may be achieved by affecting the balance of IκBα and NF-κB.

Molecular docking technology is an essential means to confirm the interaction between a compound and its target [61]. To verify whether the critical targets in the above three pathways can be combined with the internal chemical components of AST, we used SYBYL-X.2.0 to carry out molecular docking between markers and compounds that are closely related to these pathways that had a total score
greater than 4, which is a sensible standard for defining the combination of the markers and compounds. The results showed that γ-sitosterol, cycloeucalenol, kaempferol, encecalin, and cyperol bound well to the joint targets of TNF, MAPK8 (JNK), NF-κB, and IκBα in these three pathways. However, although we can determine the potential of binding between a compound and its target through this method, the biological changes of the target gene after binding are still unclear.

Because the interactions that occur among the chemical components of Astragalus granules are not clear, the advantage of Chinese medicine lies in the superimposed effect of multiple features on multiple pathways. Core genes such as TNF-α, MAPK8, IκBα, NF-κB, and PI3K were validated by ELISA, real-time quantitative PCR, and western blot. The results showed that the levels of sepsis markers IL1β, IL-6, and TNFα in the blood of model rats and the mortality rate of rats were significantly increased after tail vein injection. These phenomena are closely related to alterations in the PI3K signaling pathway, MAPK signaling pathway, and TNF signaling pathway in rats. The high mortality of rats is often accompanied by an imbalance between their own internal NF-κB and IκBα. The balance between NF-κB and IκBα can be altered by the expression of key genes such as TNF-α, IL-6, MMP9, MAPK8, and PI3K. Fortunately, Astragalus granules and their components significantly modulated mortality and altered the expression of these key genes in rats.

Indeed, the effects of cycloeucalenol, encecalin, and kaempferol are somewhat deviated compared to the effects of Astragalus granules. These compounds exhibit some targeting of the regulation of these key genes. For example, although cycloeucalenol has a modulating effect on most

Figure 11: PCR results (n = 3). (a–g) Effects of Astragalus granules and their components on the expression levels of IL-6, MMP9, TNF-α, MAPK8, IκBα, NF-κB, and PI3K mRNA in the blood of rats in each group. a: control group; b: LPS group; c: LPS + Astragalus granules group; d: LPS + excipient group; e: LPS + cycloeucalenol group; f: LPS + encecalin group; g: LPS + kaempferol group. *P < 0.05, compared with LPS group. **P < 0.01, compared with LPS group. ***P < 0.01, compared with control group.
indicators, it has a weaker modulating effect on NF-κB. Encecalin can modulate MMP9, TNF-α, PI3K, and NF-κB. Kaempferol is more likely to affect targets such as IL-6 and NF-κB. Therefore, to some extent, cycloeucalenol, encecalin, and kaempferol can all reduce the expression of inflammatory factors and reduce the mortality rate in rats.
This demonstrates that the pharmacological action of Astragalus granules may be the result of the combined action of its internal chemotactic components such as cyclo-eucalenol, encecalin, and kaempferol. The pharmacological effects of Astragalus granules cannot be replaced by their own internal chemotactic components. Of course, the results of this study are subject to the dose-effect relationship. In the future, we will further clarify the respective advantages of Astragalus granules and chemically combined ingredients to provide new ideas and approaches for clinical use.

4. Conclusions

This study is based on network pharmacology and used the TCMSP, BATMAN, GeneCards, MalaCards, and OMIM databases to obtain AST and sepsis-related targets to identify shared genes between them. The AST could affect the TNF, PI3K, and MAPK pathway cascade responses centred on IκBα and NF-κB, attenuate the expression of IL-6 and MMP9, and interfere with the inflammatory response during sepsis.

Data Availability

The data used to support the findings of the study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Haiyang Yu and Qihua Ling contributed equally to this study.

Acknowledgments

This study was supported by the Science and Technology Plan Project of Guizhou Province ([2017]1401), National Natural Science Foundation of China (82074156), Medical Innovation Research Special Project of Shanghai Science and Technology Commission (20Y21900300 and 21Y11920500), and Special Project on Research Innovation and Exploration of Guizhou University of Traditional Chinese Medicine (2019YFC171250101).

References

[1] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (sepsis-3),” JAMA, vol. 315, no. 8, pp. 801–810, 2016.
[2] F. R. Machado, A. B. Cavalcanti, F. A. Bozza et al., “The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREVence Assessment Database, SPREAD): an observational study,” The Lancet Infectious Diseases, vol. 17, no. 11, pp. 1180–1189, 2017.
[3] K. Reinhart, R. Daniels, N. Kissoon, F. R. Machado, R. D. Schachter, and S. Finfer, “Recognizing sepsis as a global health priority - a WHO resolution,” New England Journal of Medicine, vol. 377, no. 5, pp. 414–417, 2017.
[4] L. Chen, Y. Lu, L. Zhao et al., “Curcumin attenuates sepsis-induced acute organ dysfunction by preventing inflammation and enhancing the suppressive function of Tregs,” International Immunopharmacology, vol. 61, pp. 1–7, 2018.
[5] A. Conway-Morris, J. Wilson, and M. Shankar-Hari, “Immune activation in sepsis,” Critical Care Clinics, vol. 34, no. 1, pp. 29–42, 2018.
[6] S. Madoiwa, “Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC,” Journal of Intensive Care, vol. 3, no. 1, p. 8, 2015.
[7] S. Weis, A. R. Carlos, M. R. Moita et al., “Metabolic adaptation establishes disease tolerance to sepsis,” Cell, vol. 169, no. 7, pp. 1263–1275, 2017.
[8] S. Xie, T. Yang, Z. Wang et al., “Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling,” International Immunopharmacology, vol. 78, Article ID 106066, 2020.
[9] X. Xu, S. Rui, C. Chen et al., “Protective effects of astragalus polysaccharide nanoparticles on septic cardiac dysfunction through inhibition of TLR4/NF-kB signaling pathway,” International Journal of Biological Macromolecules, vol. 153, pp. 977–985, 2020.
[10] X.-h. Gao, X.-x. Xu, R. Pan et al., “Qi-Shao-Shuang-Gan, a combination of Astragalus membranaceus saponins with paonia lactiflora glycosides, ameliorates polymicrobial sepsis induced by cecal ligation and puncture in mice,” Inflammation, vol. 34, no. 1, pp. 10–21, 2011.
[11] Y. Han, J. Xu, X. Zhang, T. J. Zhang, Y. J. Ren, and C. X. Liu, “Network pharmacology-based study on mechanism of Yuanhu Zhitong dropping pills in the treatment of primary dysmenorrhea,” Yao Xue Xue Bao, vol. 51, no. 3, pp. 380–387, 2016.
[12] R.-X. Zhong, Z.-h. Ding, Y.-n. Yang et al., “Study on the pharmacodynamic material basis and mechanisms of Ju-HongTan-Ke liquid for the treatment of “phlegm, cough, and asthma” based on network pharmacology,” Acta Pharmaceutica Sinica, vol. 55, no. 9, pp. 2134–2144, 2020.
[13] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 13, p. 13, 2014.
[14] Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TCM: a Bioinformatics analysis Tool for molecular mechAnism of tradi-tional Chinese medicine,” Scientific Reports, vol. 6, no. 1, p. 21146, 2016.
[15] P. N. Morcos, L. Yu, K. Bogman et al., “Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alsetnilib: results from an absolute bioavailability and mass balance study in healthy subjects,” Xenobiotica, vol. 47, no. 3, pp. 217–229, 2017.
[16] S. Tian, Y. Li, J. Wang, J. Zhang, and T. Hou, “ADME evaluation in drug discovery. 9. Prediction of oral bioavailibility in humans based on molecular properties and structural fingerprints,” Molecular Pharmaceutics, vol. 8, no. 3, pp. 841–851, 2011.
[17] S. Tian, J. Wang, Y. Li, X. Xu, and T. Hou, “Drug-likeness analysis of traditional Chinese medicines: prediction of drug-likeness using machine learning approaches,” Molecular Pharmaceutics, vol. 9, no. 10, pp. 2875–2886, 2012.
[18] M. Gibaldi and G. Levy, “Pharmacokinetics in clinical practice,” JAMA, vol. 235, no. 18, pp. 1987–1992, 1976.
[19] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide
Evidence-Based Complementary and Alternative Medicine 21

[20] Q. Guo, M. Zhong, H. Xu, X. Mao, Y. Zhang, and N. Lin, “A systems biology perspective on the molecular mechanisms underlying the therapeutic effects of buyang huanwuo decoction on ischemic stroke,” Rejuvenation Research, vol. 18, no. 4, pp. 313–325, 2015.

[21] G. Y. Lin, H. C. Yao, and X. N. Zheng, “Virtual screening for effective components in commonly used anti-diabetic traditional Chinese medicines based on molecular docking technology,” Chin J Exp Tradit Med Formulae, vol. 21, no. 15, pp. 202–206, 2015.

[22] J. Liang, “Study on preparation technology of Astragalus granule,” Heilongjiang Medicine Journal, vol. 25, no. 3, pp. 413–414, 2012.

[23] J. Peng, J. Zhang, L. Zhang, Y. Tian, Y. Li, and L. Qiao, “Exploration of some issues of technical specifications for the study of the efficacy and toxicology of Chinese medicines,” in Proceedings of the 12th National Neuropsychopharmacology Academic Exchange Conference, p. 2, Zunyi, China, 2006.

[24] P.-C. Liao, M.-H. Lai, K.-P. Hsu et al., “Identification of β-sitosterol as an in vitro anti-inflammatory constituent in moringa oleifera,” Journal of Agricultural and Food Chemistry, vol. 66, no. 41, pp. 10748–10759, 2018.

[25] T. Horiiuchi, H. Mitoma, S.-i. Harashima, H. Tsukamoto, and T. Shimoda, “Transmembrane TNF-α: structure, function and interaction with anti-TNF agents,” Rheumatology, vol. 49, no. 7, pp. 1215–1228, 2010.

[26] W. Fujita-Hamabe and S. Tokuyama, “The involvement of cleavage of neural cell adhesion molecule in neuronal death under oxidative stress conditions in cultured cortical neurons,” Biological and Pharmaceutical Bulletin, vol. 35, no. 4, pp. 624–628, 2012.

[27] J. Li, S. Wang, L. Bai et al., “Novel role for the immune-proteasome subunit PSMB10 in angiotensin II-induced atrial fibrillation in mice,” Hypertension, vol. 71, no. 5, pp. 866–876, 2018.

[28] J. Li, L. Chen, T. Wu, and G. Li, “Recent progress regarding kaempferol for the treatment of various diseases,” Experimental and Therapeutic Medicine, vol. 18, no. 4, 2019.
Akt/GSK-3β/mTOR pathway in rats,” *BioMed Research International*, vol. 2019, Article ID 5240898, 9 pages, 2019.

[49] Q. Zheng, Y.-C. Wang, Q.-X. Liu et al., “FK866 attenuates sepsis-induced acute lung injury through c-jun-N-terminal kinase (JNK)-dependent autophagy,” *Life Sciences*, vol. 250, Article ID 117531, 2020.

[50] M. Pang, Y. Yuan, D. Wang et al., “Recombinant CC16 protein inhibits the production of pro-inflammatory cytokines via NF-κB and p38 MAPK pathways in LPS-activated RAW264.7 macrophages,” *Acta Biochimica et Biophysica Sinica*, vol. 49, no. 5, pp. 435–443, 2017.

[51] J. Steinberg, J. Halter, H. Schiller et al., “Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model,” *Shock*, vol. 24, no. 4, pp. 348–356, 2005.

[52] T. C. van der Pouw Kraan, L. C. Boeije, R. J. Smeenk, J. Wijdenes, and L. A. Aarden, “Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production,” *Journal of Experimental Medicine*, vol. 181, no. 2, pp. 775–779, 1995.

[53] P. K. Chatterjee, Y. Al-Abed, B. Sherry, and C. N. Metz, “Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation,” *American Journal of Physiology-Cell Physiology*, vol. 297, no. 5, pp. C1294–C1306, 2009.

[54] A. Miyoshi, S. Koyama, M. Sasagawa-Monden et al., “JNK and ATF4 as two important platforms for tumor necrosis factor-α-stimulated shedding of receptor for advanced glycation end products,” *The FASEB Journal*, vol. 33, no. 3, pp. 3575–3589, 2019.

[55] Z. Navratilova, V. Kolek, and M. Petrek, “Matrix metalloproteinases and their inhibitors in chronic obstructive pulmonary disease,” *Archivum Immunologiae et Therapiae Exp*., vol. 64, no. 3, pp. 177–193, 2016.

[56] M. S. Hayden and S. Ghosh, “Regulation of NF-κB by TNF family cytokines,” *Seminars in Immunology*, vol. 26, no. 3, pp. 253–266, 2014.

[57] R. Baker and S. Ghosh, “Direct activation of protein kinases by ubiquitin,” *Journal of Molecular Cell Biology*, vol. 2, no. 1, pp. 20–22, 2010.

[58] R. J. Davis, “Signal transduction by the JNK group of MAP kinases,” *Cell*, vol. 103, no. 2, pp. 239–252, 2000.

[59] X. Shang, K. Lin, R. Yu et al., “Resveratrol protects the myocardium in sepsis by activating the phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and inhibiting the nuclear factor-xb (NF-xB) signaling pathway,” *Medical Science Monitor*, vol. 25, pp. 9290–9298, 2019.

[60] C. F. Fortin, A. Cloutier, T. Ear et al., “A class IA PI3K controls inflammatory cytokine production in human neutrophils,” *European Journal of Immunology*, vol. 41, no. 6, pp. 1709–1719, 2011.

[61] L. Pinzi and G. Rastelli, “Molecular docking: shifting paradigms in drug discovery,” *International Journal of Molecular Sciences*, vol. 20, no. 18, 2019.